Belantamab mafodotin vs Ciltacabtagene autoleucel
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Multiple Myeloma
Shared mechanism: BCMA · full Multiple Myeloma pipeline
Belantamab mafodotin
Marketed by GlaxoSmithKline
NCT04246047 · Phase 3 · active, not recruiting
Patients were randomized (243 vs 251) against an active comparator and the primary endpoint of progression-free survival, assessed by an independent review committee, was met with a large separation (hazard ratio 0.41, p<0.00001). The study was open-label with no masking of participants or investigators, which keeps it below the highest grade.
Next expected readout: February 2027 · NCT05055063 (registry estimate)
Reported efficacy
Progression-free Survival (PFS) (Up to approximately 41 months): Progression-free Survival (PFS) (Up to approximately 41 months): Belantamab Mafodotin + Bortezomib (Bor) + Dexamethasone (Dex) 36.6 Months vs Daratumumab + Bor + Dex 13.4 Months (95% CI 11.1 to 17.5) (met)
Result source: NCT04246047
Ciltacabtagene autoleucel
Marketed by Johnson & Johnson under a licence from Legend Biotech Corporation
NCT04181827 · Phase 3 · active, not recruiting
This was a large randomized phase 3 trial against active standard therapy, and its primary endpoint, progression-free survival, clearly favoured cilta-cel (hazard ratio 0.26, P<0.001). However, it was open-label: patients and doctors knew which treatment was given, so the evidence is rated below the top level.
Next expected readout: February 2027 · NCT04133636 (registry estimate)
Reported efficacy
Progression Free Survival (PFS) (From randomization (Day 1) to either progressive disease or death, whichever occurred first (up to 3.9 years)): Progression-free survival: median not reached with cilta-cel vs 11.8 months with standard care (hazard ratio 0.26; 95% CI 0.18 to 0.38; P<0.001); 12-month PFS 75.9% vs 48.6% (CARTITUDE-4, N Engl J Med 2023). (met)
Result source: NCT04181827
Results for Multiple Myeloma
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
PFS, median
- Belantamab mafodotin
- 36.6 vs 13.4vs DaratumumabNCT04246047
13 other results
- 11.2 vs 7 NCT04162210
- 3.2 NCT03525678
- 3.9 NCT03525678
- 2.2 NCT03525678
- 2.8 NCT03525678
- 3.6 NCT03525678
- 5.7 NCT03525678
- 5.7 NCT05064358
- 2.8 NCT05064358
- 2.5 NCT03848845
- 2.1 NCT05064358
- 2.7 NCT05064358
- 2.8 NCT05064358
- Ciltacabtagene autoleucel
- —Trial running · NCT05257083
OS, median
- Belantamab mafodotin
- 24 vs 22.9vs Pomalidomide Plus DexamethasoneNCT04162210
7 other results
- 14 NCT03525678
- 15.3 NCT03525678
- 24.5 NCT03525678
- 20.9 NCT05064358
- 13.5 NCT05064358
- 15 NCT05064358
- 14.5 NCT05064358
- Ciltacabtagene autoleucel
- 27.0bNCT03548207
ORR
- Belantamab mafodotin
- 41% vs 36%vs Pomalidomide Plus DexamethasoneNCT04162210
35 other results
- 34% NCT03525678
- 31% NCT03525678
- 48% NCT03525678
- 30% NCT03525678
- 30% NCT03525678
- 50% NCT03544281
- 69% NCT03544281
- 69% NCT03544281
- 69% NCT03544281
- 92% NCT03544281
- 75% NCT03544281
- 62% NCT03544281
- 78% NCT03544281
- 43% NCT03848845
- 58% NCT03544281
- 50% NCT03544281
- 83% NCT03544281
- 75% NCT03544281
- 32% NCT03525678
- 33% NCT03525678
- 52% NCT03525678
- 26% NCT03525678
- 33% NCT03525678
- 33% NCT05064358
- 28% NCT05064358
- 25% NCT05064358
- 25% NCT05064358
- 43% NCT03848845
- 67% NCT03848845
- 18% NCT05064358
- 25% NCT03828292
- 50% NCT03828292
- 100% NCT03828292
- 50% NCT03828292
- 16.7% NCT04177823
- Ciltacabtagene autoleucel
- 97.1%bNCT03548207
2 other results
- 57.3% NCT05347485
- 100% NCT03548207
VGPR or better
- Belantamab mafodotin
- 25%bNCT05064358
4 other results
- 8% NCT05064358
- 18% NCT05064358
- 15% NCT05064358
- 18% NCT05064358
- Ciltacabtagene autoleucel
- 96.6%bNCT03548207
2 other results
- 94.1% NCT03548207
- 100% NCT03548207
MRD negativity
- Belantamab mafodotin
- —Trial running · NCT06679101
- Ciltacabtagene autoleucel
- 100%bNCT03548207
2 other results
- 89.7% NCT03548207
- 75% NCT03548207
- b Single-arm result: the trial had no control arm, so the number has no comparator and does not compare with a randomised result.
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
6 other shared endpoints and safety
Coverage. Belantamab mafodotin: 9 of 10 rows · Ciltacabtagene autoleucel: 8 of 10 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Belantamab mafodotin Rows use multiple source trials | Ciltacabtagene autoleucel Rows use multiple source trials |
|---|---|---|
| Clinical Benefit responder rate · % of participants No placebo or comparator arm | 38% (n=99)3.4 mg/kga,b,c,d,e NCT03525678 · Phase 2 show 9 more doses35% (n=66)3.4 mg/kg NCT03525678 · Phase 2 40% (n=99)3.4 mg/kg NCT03525678 · Phase 2 38% (n=66)3.4 mg/kg NCT03525678 · Phase 2 60% (n=25)3.4 mg/kg NCT03525678 · Phase 2 56% (n=25)3.4 mg/kg NCT03525678 · Phase 2 35% (n=97)2.5 mg/kg NCT03525678 · Phase 2 34% (n=64)2.5 mg/kg NCT03525678 · Phase 2 36% (n=97)2.5 mg/kg NCT03525678 · Phase 2 34% (n=64)2.5 mg/kg NCT03525678 · Phase 2 | 100% (n=29)a,b,c,d,e NCT03548207 · Phase 1/2 |
| Duration of Response time to event · months No placebo or comparator arm | 12.6 months3.4 mg/kga,b,c,d,e NCT03525678 · Phase 2 show 9 more doses15.9 months3.4 mg/kg NCT03525678 · Phase 2 6.2 months3.4 mg/kg NCT03525678 · Phase 2 15.9 months3.4 mg/kg NCT03525678 · Phase 2 5.3 months3.4 mg/kg NCT03525678 · Phase 2 9 months3.4 mg/kg NCT03525678 · Phase 2 12.4 months2.5 mg/kg NCT03525678 · Phase 2 6.9 months2.5 mg/kg NCT03525678 · Phase 2 12.5 months2.5 mg/kg NCT03525678 · Phase 2 11 months2.5 mg/kg NCT03525678 · Phase 2 | NA monthsa,b,c,d,e NCT03548207 · Phase 1/2 |
| ORR responder rate · % of participants No placebo or comparator arm | 34% (n=99)3.4 mg/kga,b,c,d,e NCT03525678 · Phase 2 show 9 more doses30% (n=66)3.4 mg/kg NCT03525678 · Phase 2 32% (n=99)3.4 mg/kg NCT03525678 · Phase 2 26% (n=66)3.4 mg/kg NCT03525678 · Phase 2 48% (n=25)3.4 mg/kg NCT03525678 · Phase 2 52% (n=25)3.4 mg/kg NCT03525678 · Phase 2 31% (n=97)2.5 mg/kg NCT03525678 · Phase 2 30% (n=64)2.5 mg/kg NCT03525678 · Phase 2 33% (n=97)2.5 mg/kg NCT03525678 · Phase 2 33% (n=64)2.5 mg/kg NCT03525678 · Phase 2 | 100% (n=8)a,b,c,d,e NCT03548207 · Phase 1/2 show 1 more dose97.1% (n=68) NCT03548207 · Phase 1/2 |
| Overall Survival time to event · months No placebo or comparator arm | 14 months3.4 mg/kga,b,c,d,e NCT03525678 · Phase 2 | NA monthsa,b,c,d,e NCT03548207 · Phase 1/2 |
| PFS time to event · months No placebo or comparator arm | 3.2 months3.4 mg/kga,b,c,d,e NCT03525678 · Phase 2 show 5 more doses3.9 months3.4 mg/kg NCT03525678 · Phase 2 3.6 months3.4 mg/kg NCT03525678 · Phase 2 5.7 months3.4 mg/kg NCT03525678 · Phase 2 2.2 months2.5 mg/kg NCT03525678 · Phase 2 2.8 months2.5 mg/kg NCT03525678 · Phase 2 | NA monthsa,b,c,d,e NCT03548207 · Phase 1/2 |
| VGPR or Better responder rate · % of participants No placebo or comparator arm | 25% (n=40)2.5 mg/kg Q3Wa,b,c,e NCT05064358 · Phase 2 · registry result, not featured evidence show 4 more doses8% (n=40)2.5 mg/kg Q6W NCT05064358 · Phase 2 · registry result, not featured evidence 18% (n=40)1.9 mg/kg Q3W NCT05064358 · Phase 2 · registry result, not featured evidence 15% (n=40)1.9 mg/kg Q6W NCT05064358 · Phase 2 · registry result, not featured evidence 18% (n=17)1.9 mg/kg Q6W NCT05064358 · Phase 2 · registry result, not featured evidence · combination | 96.6% (n=29)a,b,c,e NCT03548207 · Phase 1/2 |
| Dropout rate | n/a: no completion milestonef NCT04246047 · Phase 3 · combination · Multiple Myeloma · phase 3 show 56 more results42.2% NCT04162210 · Phase 3 · Multiple Myeloma · phase 3 n/a: no completion milestone3.4 mg/kg NCT03525678 · Phase 2 n/a: no completion milestone3.4 mg/kg NCT03525678 · Phase 2 —3.4 mg/kg NCT03525678 · Phase 2 n/a: no completion milestone2.5 mg/kg NCT03525678 · Phase 2 —2.5 mg/kg NCT03525678 · Phase 2 75%2.5 mg/kg Q3W NCT05064358 · Phase 2 · registry result, not featured evidence 80%2.5 mg/kg Q6W NCT05064358 · Phase 2 · registry result, not featured evidence 82.5%1.9 mg/kg Q3W NCT05064358 · Phase 2 · registry result, not featured evidence 77.5%1.9 mg/kg Q6W NCT05064358 · Phase 2 · registry result, not featured evidence 58.8%1.9 mg/kg Q6W NCT05064358 · Phase 2 · registry result, not featured evidence · combination 50%3.4 mg/kg SINGLE NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination 66.7%3.4 mg/kg SPLIT NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination —3.4 mg/kg SPLIT NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination 77.8%2.5 mg/kg SINGLE NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination 69.2%2.5 mg/kg SPLIT NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination 50%2.5 mg/kg STRETCH NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination 69.2%2.5 mg/kg Step-Down STRETCH NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination 87.5%2.5mg/kg SINGLE NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination 69.2%2.5mg/kg SPLIT NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination —2.5 mg/kg SINGLE NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination —2.5 mg/kg SPLIT NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination —2.5 mg/kg Step-Down STRETCH NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination —2.5mg/kg SINGLE NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination —2.5mg/kg SPLIT NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination 50%1.9 mg/kg SINGLE NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination 50%1.9 mg/kg STRETCH NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination 75%1.9mg/kg SINGLE NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination 66.7%1.9mg/kg STRETCH NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination —1.9 mg/kg SINGLE NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination —1.9 mg/kg STRETCH NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination —1.9mg/kg SINGLE NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination —1.9mg/kg STRETCH NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination 42.9%3.4 mg/kg + 200 mg NCT03848845 · Phase 1/2 · registry result, not featured evidence · combination 50%2.5 mg/kg + 200 mg NCT03848845 · Phase 1/2 · registry result, not featured evidence · combination 32.1%2.5 mg/kg + 200 mg NCT03848845 · Phase 1/2 · registry result, not featured evidence · combination —2.5 mg/kg + 200 mg NCT03848845 · Phase 1/2 · registry result, not featured evidence · combination 25%3.4 mg/kg NCT03828292 · Phase 1 · registry result, not featured evidence 0%2.5 mg/kg NCT03828292 · Phase 1 · registry result, not featured evidence —2.5 mg/kg + Bor/Dex NCT03828292 · Phase 1 · registry result, not featured evidence · combination —2.5 mg/kg + Pom/Dex NCT03828292 · Phase 1 · registry result, not featured evidence · combination —2.5 mg/kg + Bor/Dex NCT03828292 · Phase 1 · registry result, not featured evidence · combination —2.5 mg/kg + Pom/Dex NCT03828292 · Phase 1 · registry result, not featured evidence · combination 33.3% NCT04177823 · Phase 1 · registry result, not featured evidence 16.7%4.60 mg/kg NCT02064387 · Phase 1 · registry result, not featured evidence 33.3%3.40 mg/kg NCT02064387 · Phase 1 · registry result, not featured evidence —3.40 mg/kg NCT02064387 · Phase 1 · registry result, not featured evidence —3.40 mg/kg NCT02064387 · Phase 1 · registry result, not featured evidence 25%2.50 mg/kg NCT02064387 · Phase 1 · registry result, not featured evidence 0%1.92 mg/kg NCT02064387 · Phase 1 · registry result, not featured evidence 0%0.96 mg/kg NCT02064387 · Phase 1 · registry result, not featured evidence 0%0.48 mg/kg NCT02064387 · Phase 1 · registry result, not featured evidence 0%0.24 mg/kg NCT02064387 · Phase 1 · registry result, not featured evidence 0%0.12 mg/kg NCT02064387 · Phase 1 · registry result, not featured evidence 0%0.06 mg/kg NCT02064387 · Phase 1 · registry result, not featured evidence 0%0.03 mg/kg NCT02064387 · Phase 1 · registry result, not featured evidence | n/a: no completion milestoneg NCT04181827 · Phase 3 · Multiple Myeloma · phase 3 show 4 more resultsn/a: no completion milestonePhase 1b (US Population) NCT03548207 · Phase 1/2 n/a: no completion milestonePhase 2 (Japan Population) NCT03548207 · Phase 1/2 n/a: no completion milestonePhase 2 (US Population) NCT03548207 · Phase 1/2 n/a: no completion milestone NCT05347485 · Phase 2 · registry result, not featured evidence |
| Discontinued due to AEs | —f NCT04246047 · Phase 3 · combination · Multiple Myeloma · phase 3 show 56 more results— NCT04162210 · Phase 3 · Multiple Myeloma · phase 3 —3.4 mg/kg NCT03525678 · Phase 2 —3.4 mg/kg NCT03525678 · Phase 2 —3.4 mg/kg NCT03525678 · Phase 2 —2.5 mg/kg NCT03525678 · Phase 2 —2.5 mg/kg NCT03525678 · Phase 2 —2.5 mg/kg Q3W NCT05064358 · Phase 2 · registry result, not featured evidence —2.5 mg/kg Q6W NCT05064358 · Phase 2 · registry result, not featured evidence —1.9 mg/kg Q3W NCT05064358 · Phase 2 · registry result, not featured evidence —1.9 mg/kg Q6W NCT05064358 · Phase 2 · registry result, not featured evidence —1.9 mg/kg Q6W NCT05064358 · Phase 2 · registry result, not featured evidence · combination —3.4 mg/kg SINGLE NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination —3.4 mg/kg SPLIT NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination —3.4 mg/kg SPLIT NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination —2.5 mg/kg SINGLE NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination —2.5 mg/kg SPLIT NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination —2.5 mg/kg STRETCH NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination —2.5 mg/kg Step-Down STRETCH NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination —2.5mg/kg SINGLE NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination —2.5mg/kg SPLIT NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination —2.5 mg/kg SINGLE NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination —2.5 mg/kg SPLIT NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination —2.5 mg/kg Step-Down STRETCH NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination —2.5mg/kg SINGLE NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination —2.5mg/kg SPLIT NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination —1.9 mg/kg SINGLE NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination —1.9 mg/kg STRETCH NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination —1.9mg/kg SINGLE NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination —1.9mg/kg STRETCH NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination —1.9 mg/kg SINGLE NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination —1.9 mg/kg STRETCH NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination —1.9mg/kg SINGLE NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination —1.9mg/kg STRETCH NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination —3.4 mg/kg + 200 mg NCT03848845 · Phase 1/2 · registry result, not featured evidence · combination —2.5 mg/kg + 200 mg NCT03848845 · Phase 1/2 · registry result, not featured evidence · combination —2.5 mg/kg + 200 mg NCT03848845 · Phase 1/2 · registry result, not featured evidence · combination —2.5 mg/kg + 200 mg NCT03848845 · Phase 1/2 · registry result, not featured evidence · combination —3.4 mg/kg NCT03828292 · Phase 1 · registry result, not featured evidence —2.5 mg/kg NCT03828292 · Phase 1 · registry result, not featured evidence —2.5 mg/kg + Bor/Dex NCT03828292 · Phase 1 · registry result, not featured evidence · combination —2.5 mg/kg + Pom/Dex NCT03828292 · Phase 1 · registry result, not featured evidence · combination —2.5 mg/kg + Bor/Dex NCT03828292 · Phase 1 · registry result, not featured evidence · combination —2.5 mg/kg + Pom/Dex NCT03828292 · Phase 1 · registry result, not featured evidence · combination — NCT04177823 · Phase 1 · registry result, not featured evidence —4.60 mg/kg NCT02064387 · Phase 1 · registry result, not featured evidence —3.40 mg/kg NCT02064387 · Phase 1 · registry result, not featured evidence —3.40 mg/kg NCT02064387 · Phase 1 · registry result, not featured evidence —3.40 mg/kg NCT02064387 · Phase 1 · registry result, not featured evidence —2.50 mg/kg NCT02064387 · Phase 1 · registry result, not featured evidence —1.92 mg/kg NCT02064387 · Phase 1 · registry result, not featured evidence —0.96 mg/kg NCT02064387 · Phase 1 · registry result, not featured evidence —0.48 mg/kg NCT02064387 · Phase 1 · registry result, not featured evidence —0.24 mg/kg NCT02064387 · Phase 1 · registry result, not featured evidence —0.12 mg/kg NCT02064387 · Phase 1 · registry result, not featured evidence —0.06 mg/kg NCT02064387 · Phase 1 · registry result, not featured evidence —0.03 mg/kg NCT02064387 · Phase 1 · registry result, not featured evidence | —g NCT04181827 · Phase 3 · Multiple Myeloma · phase 3 show 4 more results—Phase 1b (US Population) NCT03548207 · Phase 1/2 —Phase 2 (Japan Population) NCT03548207 · Phase 1/2 —Phase 2 (US Population) NCT03548207 · Phase 1/2 — NCT05347485 · Phase 2 · registry result, not featured evidence |
| Serious AEs | 50%f NCT04246047 · Phase 3 · combination · Multiple Myeloma · phase 3 show 56 more results46.5% NCT04162210 · Phase 3 · Multiple Myeloma · phase 3 53.5%3.4 mg/kg NCT03525678 · Phase 2 62.5%3.4 mg/kg NCT03525678 · Phase 2 100%3.4 mg/kg NCT03525678 · Phase 2 45.3%2.5 mg/kg NCT03525678 · Phase 2 100%2.5 mg/kg NCT03525678 · Phase 2 43.6%2.5 mg/kg Q3W NCT05064358 · Phase 2 · registry result, not featured evidence 53.8%2.5 mg/kg Q6W NCT05064358 · Phase 2 · registry result, not featured evidence 42.5%1.9 mg/kg Q3W NCT05064358 · Phase 2 · registry result, not featured evidence 40%1.9 mg/kg Q6W NCT05064358 · Phase 2 · registry result, not featured evidence 23.5%1.9 mg/kg Q6W NCT05064358 · Phase 2 · registry result, not featured evidence · combination 56.3%3.4 mg/kg SINGLE NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination 50%3.4 mg/kg SPLIT NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination 0%3.4 mg/kg SPLIT NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination 72.2%2.5 mg/kg SINGLE NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination 53.8%2.5 mg/kg SPLIT NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination 50%2.5 mg/kg STRETCH NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination 50%2.5 mg/kg Step-Down STRETCH NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination 62.5%2.5mg/kg SINGLE NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination 46.2%2.5mg/kg SPLIT NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination 0%2.5 mg/kg SINGLE NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination 0%2.5 mg/kg SPLIT NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination 25%2.5 mg/kg Step-Down STRETCH NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination 50%2.5mg/kg SINGLE NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination 0%2.5mg/kg SPLIT NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination 66.7%1.9 mg/kg SINGLE NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination 66.7%1.9 mg/kg STRETCH NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination 50%1.9mg/kg SINGLE NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination 50%1.9mg/kg STRETCH NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination 25%1.9 mg/kg SINGLE NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination 50%1.9 mg/kg STRETCH NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination 0%1.9mg/kg SINGLE NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination 33.3%1.9mg/kg STRETCH NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination 71.4%3.4 mg/kg + 200 mg NCT03848845 · Phase 1/2 · registry result, not featured evidence · combination 66.7%2.5 mg/kg + 200 mg NCT03848845 · Phase 1/2 · registry result, not featured evidence · combination 17.9%2.5 mg/kg + 200 mg NCT03848845 · Phase 1/2 · registry result, not featured evidence · combination 0%2.5 mg/kg + 200 mg NCT03848845 · Phase 1/2 · registry result, not featured evidence · combination 0%3.4 mg/kg NCT03828292 · Phase 1 · registry result, not featured evidence 50%2.5 mg/kg NCT03828292 · Phase 1 · registry result, not featured evidence 0%2.5 mg/kg + Bor/Dex NCT03828292 · Phase 1 · registry result, not featured evidence · combination 25%2.5 mg/kg + Pom/Dex NCT03828292 · Phase 1 · registry result, not featured evidence · combination 50%2.5 mg/kg + Bor/Dex NCT03828292 · Phase 1 · registry result, not featured evidence · combination 0%2.5 mg/kg + Pom/Dex NCT03828292 · Phase 1 · registry result, not featured evidence · combination 16.7% NCT04177823 · Phase 1 · registry result, not featured evidence 50%4.60 mg/kg NCT02064387 · Phase 1 · registry result, not featured evidence 33.3%3.40 mg/kg NCT02064387 · Phase 1 · registry result, not featured evidence 48.6%3.40 mg/kg NCT02064387 · Phase 1 · registry result, not featured evidence 50%3.40 mg/kg NCT02064387 · Phase 1 · registry result, not featured evidence 50%2.50 mg/kg NCT02064387 · Phase 1 · registry result, not featured evidence 50%1.92 mg/kg NCT02064387 · Phase 1 · registry result, not featured evidence 0%0.96 mg/kg NCT02064387 · Phase 1 · registry result, not featured evidence 25%0.48 mg/kg NCT02064387 · Phase 1 · registry result, not featured evidence 25%0.24 mg/kg NCT02064387 · Phase 1 · registry result, not featured evidence 25%0.12 mg/kg NCT02064387 · Phase 1 · registry result, not featured evidence 0%0.06 mg/kg NCT02064387 · Phase 1 · registry result, not featured evidence 0%0.03 mg/kg NCT02064387 · Phase 1 · registry result, not featured evidence | 47.1%g NCT04181827 · Phase 3 · Multiple Myeloma · phase 3 show 4 more results37.9%Phase 1b (US Population) NCT03548207 · Phase 1/2 11.1%Phase 2 (Japan Population) NCT03548207 · Phase 1/2 61.8%Phase 2 (US Population) NCT03548207 · Phase 1/2 51.2% NCT05347485 · Phase 2 · registry result, not featured evidence |
| Most frequent reported AEs | f thrombocytopenia 69% vision blurred 66.1% dry eye 50.8% NCT04246047 · Phase 3 · combination · Multiple Myeloma · phase 3 show 56 more resultsvision blurred 48.4% dry eye 37.8% foreign body sensation in eyes 36.9% NCT04162210 · Phase 3 · Multiple Myeloma · phase 3 2.5 mg/kg Q3W vision blurred 41% dry eye 38.5% eye irritation 28.2% NCT05064358 · Phase 2 · registry result, not featured evidence 2.5 mg/kg Q6W vision blurred 46.2% thrombocytopenia 33.3% anaemia 30.8% NCT05064358 · Phase 2 · registry result, not featured evidence 1.9 mg/kg Q3W thrombocytopenia 42.5% anaemia 30% dry eye 30% NCT05064358 · Phase 2 · registry result, not featured evidence 1.9 mg/kg Q6W anaemia 37.5% dry eye 30% eye irritation 27.5% NCT05064358 · Phase 2 · registry result, not featured evidence 1.9 mg/kg Q6W vision blurred 52.9% dry eye 47.1% eye irritation 29.4% NCT05064358 · Phase 2 · registry result, not featured evidence · combination 3.4 mg/kg SINGLE keratopathy 93.8% thrombocytopenia 56.3% neuropathy peripheral 50% NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination 3.4 mg/kg SPLIT keratopathy 83.3% thrombocytopenia 75% fatigue 41.7% NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination 3.4 mg/kg SPLIT abdominal discomfort 0% abdominal distension 0% abdominal pain 0% NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination 2.5 mg/kg SINGLE keratopathy 83.3% vision blurred 66.7% platelet count decreased 50% NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination 2.5 mg/kg SPLIT keratopathy 76.9% thrombocytopenia 69.2% vision blurred 38.5% NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination 2.5 mg/kg STRETCH keratopathy 100% platelet count decreased 58.3% gamma-glutamyltransferase increased 50% NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination 2.5 mg/kg Step-Down STRETCH keratopathy 100% platelet count decreased 58.3% diarrhoea 50% NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination 2.5mg/kg SINGLE keratopathy 68.8% fatigue 43.8% thrombocytopenia 43.8% NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination 2.5mg/kg SPLIT keratopathy 92.3% vision blurred 53.8% diarrhoea 46.2% NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination 2.5 mg/kg SINGLE abdominal discomfort 0% abdominal distension 0% abdominal pain 0% NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination 2.5 mg/kg SPLIT abdominal discomfort 0% abdominal distension 0% abdominal pain 0% NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination 2.5 mg/kg Step-Down STRETCH abdominal discomfort 0% abdominal distension 0% abdominal pain 0% NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination 2.5mg/kg SINGLE abdominal discomfort 0% abdominal distension 0% abdominal pain 0% NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination 2.5mg/kg SPLIT abdominal discomfort 0% abdominal distension 0% abdominal pain 0% NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination 1.9 mg/kg SINGLE keratopathy 91.7% platelet count decreased 75% constipation 66.7% NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination 1.9 mg/kg STRETCH keratopathy 75% diarrhoea 50% platelet count decreased 50% NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination 1.9mg/kg SINGLE diarrhoea 75% keratopathy 75% abdominal pain 50% NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination 1.9mg/kg STRETCH keratopathy 75% diarrhoea 41.7% insomnia 41.7% NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination 1.9 mg/kg SINGLE abdominal discomfort 0% abdominal distension 0% abdominal pain 0% NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination 1.9 mg/kg STRETCH abdominal discomfort 0% abdominal distension 0% abdominal pain 0% NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination 1.9mg/kg SINGLE abdominal discomfort 0% abdominal distension 0% abdominal pain 0% NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination 1.9mg/kg STRETCH abdominal discomfort 0% abdominal distension 0% abdominal pain 0% NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination 3.4 mg/kg + 200 mg keratopathy 85.7% pyrexia 57.1% anaemia 42.9% NCT03848845 · Phase 1/2 · registry result, not featured evidence · combination 2.5 mg/kg + 200 mg keratopathy 100% anaemia 66.7% blepharitis 50% NCT03848845 · Phase 1/2 · registry result, not featured evidence · combination 2.5 mg/kg + 200 mg keratopathy 71.4% pyrexia 35.7% vision blurred 35.7% NCT03848845 · Phase 1/2 · registry result, not featured evidence · combination 2.5 mg/kg + 200 mg alanine aminotransferase increased 0% anaemia 0% arthralgia 0% NCT03848845 · Phase 1/2 · registry result, not featured evidence · combination 3.4 mg/kg diarrhoea 50% enterocolitis 50% headache 50% NCT03828292 · Phase 1 · registry result, not featured evidence 2.5 mg/kg platelet count decreased 100% alanine aminotransferase increased 50% aspartate aminotransferase increased 50% NCT03828292 · Phase 1 · registry result, not featured evidence 2.5 mg/kg + Bor/Dex thrombocytopenia 100% diarrhoea 66.7% insomnia 66.7% NCT03828292 · Phase 1 · registry result, not featured evidence · combination 2.5 mg/kg + Pom/Dex constipation 50% neutrophil count decreased 50% oedema peripheral 50% NCT03828292 · Phase 1 · registry result, not featured evidence · combination 2.5 mg/kg + Bor/Dex abdominal pain upper 0% abnormal faeces 0% alanine aminotransferase increased 0% NCT03828292 · Phase 1 · registry result, not featured evidence · combination 2.5 mg/kg + Pom/Dex abdominal pain upper 0% abnormal faeces 0% alanine aminotransferase increased 0% NCT03828292 · Phase 1 · registry result, not featured evidence · combination blood lactate dehydrogenase increased 66.7% hyponatraemia 66.7% lymphocyte count decreased 66.7% NCT04177823 · Phase 1 · registry result, not featured evidence 4.60 mg/kg thrombocytopenia 83.3% aspartate aminotransferase increased 66.7% fatigue 66.7% NCT02064387 · Phase 1 · registry result, not featured evidence 3.40 mg/kg vision blurred 100% aspartate aminotransferase increased 66.7% chills 66.7% NCT02064387 · Phase 1 · registry result, not featured evidence 3.40 mg/kg vision blurred 51.4% cough 40% aspartate aminotransferase increased 37.1% NCT02064387 · Phase 1 · registry result, not featured evidence 3.40 mg/kg vision blurred 33.3% anaemia 16.7% blood creatine phosphokinase increased 16.7% NCT02064387 · Phase 1 · registry result, not featured evidence 2.50 mg/kg anaemia 37.5% fatigue 37.5% nausea 37.5% NCT02064387 · Phase 1 · registry result, not featured evidence 1.92 mg/kg nausea 75% vision blurred 75% chills 50% NCT02064387 · Phase 1 · registry result, not featured evidence 0.96 mg/kg anaemia 66.7% fatigue 66.7% chills 33.3% NCT02064387 · Phase 1 · registry result, not featured evidence 0.48 mg/kg arthralgia 50% back pain 25% decreased appetite 25% NCT02064387 · Phase 1 · registry result, not featured evidence 0.24 mg/kg fatigue 50% nausea 50% anaemia 25% NCT02064387 · Phase 1 · registry result, not featured evidence 0.12 mg/kg cough 50% hypercalcaemia 50% nausea 50% NCT02064387 · Phase 1 · registry result, not featured evidence 0.06 mg/kg anaemia 100% diarrhoea 100% hyperuricaemia 100% NCT02064387 · Phase 1 · registry result, not featured evidence 0.03 mg/kg fatigue 100% neutropenia 100% osteonecrosis of jaw 100% NCT02064387 · Phase 1 · registry result, not featured evidence | g neutropenia 89.9% cytokine release syndrome 62% thrombocytopenia 54.3% NCT04181827 · Phase 3 · Multiple Myeloma · phase 3 show 4 more resultsneutropenia 80.5% anaemia 59.8% cytokine release syndrome 57.3% NCT05347485 · Phase 2 · registry result, not featured evidence |
Notes
- aThis study reports multiple eligible drug arms; no representative arm has been reviewed.
- bTrial phases differ: Phase 2 versus Phase 1/2.
- cPopulation comparability has not been reviewed for both studies.
- dTreatment context has not been resolved for both arms.
- eThe assessment timepoint is not available for both results.
- fPopulation comparability has not been reviewed for 55 of these studies.
- gPopulation comparability has not been reviewed for 4 of these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Belantamab mafodotin
show 15 more results
show 11 more results
show 2 more results
show 2 more results
show 2 more results
+ 304 further endpoints in the CSV export.
Ciltacabtagene autoleucel
show 27 more results
show 27 more results
show 27 more results
show 7 more results
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Belantamab mafodotin's landscape · Ciltacabtagene autoleucel's landscape